Formulary guidance and transparency from P&T to point of care


Reality Check on Opioid Dependence

Market access for opioid dependence treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, more than 42% of the lives under commercial formularies are covered without utilization management restrictions
  • Class Trends: To combat the opioid crisis, CMS in June 2018 guidance included an Information Bulletin providing states with considerations when designing approaches to covering critical treatment services for Medicaid-eligible infants with Neonatal Abstinence Syndrome, a post-natal opioid withdrawal syndrome that causes lengthy and costly hospital stays 
  • Key Findings: Buprenorphine and naloxone products compete for position given their relative clinical parity and functionality. Demand for opioid dependence treatments will increase due to favorable regulatory changes

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.